FDA expands early breast cancer indication for abemaciclib with endocrine therapy

Coverage, in order

1. 1d ago
   FDA Drug Safety / Drugs feed indie

   FDA expands early breast cancer indication for abemaciclib with endocrine therapy

   On March 3, 2023, the Food and Drug Administration (FDA) approved abemaciclib (Verzenio, Eli Lilly and Company) with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.